<DOC>
	<DOC>NCT01606059</DOC>
	<brief_summary>The purpose of this study is to evaluate safety and pharmacokinetics of DW-0919 and DW-0920 in healthy male volunteers under fasting condition.</brief_summary>
	<brief_title>Phase 1 Study of DW-0919 &amp; DW-0920 in Healthy Male Volunteers Under Fasting Condition</brief_title>
	<detailed_description />
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Adult males aged 20 to 55 years at screening. No significant congenital/chronic disease. No symptoms in physical examination. Appropriate subjects as determined by past medical history, laboratory tests, serology and urinalysis. Be able to understand the objective, method of the study, the characteristics of investigational drug, and comply with the requirement of the study. Subject must provide written informed consent prior to study participation. History of Hyperreactivity with drug ingredients(acetaminophen, tramadol) or opioids. History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hematooncologic, cardiovascular or psychiatric or cognitive disorders. History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or disorders of absorption, distribution, metabolism, excretion.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>